Tags

Type your tag names separated by a space and hit enter

[The effect of n-3 fatty acid administration on selected indicators of cardiovascular disease risk in patients with type 2 diabetes mellitus].
Bratisl Lek Listy 1998; 99(1):37-42BL

Abstract

BACKGROUND

Serum triacylglycerols (TG), VLDL, HDL, fatty acid and eicosanoid spectrum are among the factors determining the risk of cardiovascular complications in NIDDM. N-3 polyunsaturated fatty acids (PUFA) are expected to have beneficial effects on these factors. In NIDDM patients there have however been previously reported (late 1980s) some adverse effects.

OBJECTIVES

Our aim was to verify the effects of n-3 PUFA in NIDDM patients using relatively low dosage.

METHODS

The investigated group included 21 NIDDM patients with dyslipoproteinemia type IV. The patients were treated for 28 days with 1.7 g EPA (eicosapentaenoic acid) + 1.15 g DHA (docosahexaenoic acid)/day (10 capsules/day of MAXEPA, Seven Seas U.K.). The lipoproteins were measured using the BIO-LACHEMA kits, the fatty acid spectrum in phospholipids was determined by gas chromatography and prostanoids (after their separation) were measured by RIA methods.

MAIN RESULTS AND CONCLUSIONS

After the MAXEPA treatment there has been a strong decrease in TG (p < 0.005) and VLDL (p < 0.002) serum levels, accompanied by a significant increase in HDL (p < 0.02). The final-to-baseline TG ratio in individual patients negatively correlated with the relative percentage of EPA in phospholipids after the treatment (p < 0.03; r = -0.474). There was no significant change in serum total cholesterol, fasting glycaemia and glycosylated hemoglobin. There was a slight, but statistically already significant (p < 0.05), rise in LDL. The relative percentage of EPA, docosapentaenoic acid and DHA in serum phospholipids increased sharply (p < 0.001, p < 0.001, p < 0.001). The increase of n-3 PUFA in individual patients was linked with the decrease in n-6 PUFA (p < 0.001; r = -0.686). The spectrum of the latter has changed also very markedly. The prostacyclin PGI2-to-thromboxane TxA2 ratio increased significantly (p < 0.001). Beneficial effects of n-3 fatty acids have prevailed and this kind of treatment seems very encouraging also in NIDDM patients. The results are logically compatible with other authors' results pattern formed in 1990s. A slight rise in serum LDL needs a more detailed discussion since only its phenotype B ("small dense LDL particles") has been recently found to be atherogenic. (Tab. 2, Fig. 5, Ref. 15.)

Authors+Show Affiliations

Klinické oddelenie Výskumného ústavu výzivy v Bratislave.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

slo

PubMed ID

9588078

Citation

Habán, P, et al. "[The Effect of N-3 Fatty Acid Administration On Selected Indicators of Cardiovascular Disease Risk in Patients With Type 2 Diabetes Mellitus]." Bratislavske Lekarske Listy, vol. 99, no. 1, 1998, pp. 37-42.
Habán P, Simoncic R, Klvanová I, et al. [The effect of n-3 fatty acid administration on selected indicators of cardiovascular disease risk in patients with type 2 diabetes mellitus]. Bratisl Lek Listy. 1998;99(1):37-42.
Habán, P., Simoncic, R., Klvanová, I., Ozdín, L., & Zideková, E. (1998). [The effect of n-3 fatty acid administration on selected indicators of cardiovascular disease risk in patients with type 2 diabetes mellitus]. Bratislavske Lekarske Listy, 99(1), pp. 37-42.
Habán P, et al. [The Effect of N-3 Fatty Acid Administration On Selected Indicators of Cardiovascular Disease Risk in Patients With Type 2 Diabetes Mellitus]. Bratisl Lek Listy. 1998;99(1):37-42. PubMed PMID: 9588078.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The effect of n-3 fatty acid administration on selected indicators of cardiovascular disease risk in patients with type 2 diabetes mellitus]. AU - Habán,P, AU - Simoncic,R, AU - Klvanová,I, AU - Ozdín,L, AU - Zideková,E, PY - 1998/5/20/pubmed PY - 1998/5/20/medline PY - 1998/5/20/entrez SP - 37 EP - 42 JF - Bratislavske lekarske listy JO - Bratisl Lek Listy VL - 99 IS - 1 N2 - BACKGROUND: Serum triacylglycerols (TG), VLDL, HDL, fatty acid and eicosanoid spectrum are among the factors determining the risk of cardiovascular complications in NIDDM. N-3 polyunsaturated fatty acids (PUFA) are expected to have beneficial effects on these factors. In NIDDM patients there have however been previously reported (late 1980s) some adverse effects. OBJECTIVES: Our aim was to verify the effects of n-3 PUFA in NIDDM patients using relatively low dosage. METHODS: The investigated group included 21 NIDDM patients with dyslipoproteinemia type IV. The patients were treated for 28 days with 1.7 g EPA (eicosapentaenoic acid) + 1.15 g DHA (docosahexaenoic acid)/day (10 capsules/day of MAXEPA, Seven Seas U.K.). The lipoproteins were measured using the BIO-LACHEMA kits, the fatty acid spectrum in phospholipids was determined by gas chromatography and prostanoids (after their separation) were measured by RIA methods. MAIN RESULTS AND CONCLUSIONS: After the MAXEPA treatment there has been a strong decrease in TG (p < 0.005) and VLDL (p < 0.002) serum levels, accompanied by a significant increase in HDL (p < 0.02). The final-to-baseline TG ratio in individual patients negatively correlated with the relative percentage of EPA in phospholipids after the treatment (p < 0.03; r = -0.474). There was no significant change in serum total cholesterol, fasting glycaemia and glycosylated hemoglobin. There was a slight, but statistically already significant (p < 0.05), rise in LDL. The relative percentage of EPA, docosapentaenoic acid and DHA in serum phospholipids increased sharply (p < 0.001, p < 0.001, p < 0.001). The increase of n-3 PUFA in individual patients was linked with the decrease in n-6 PUFA (p < 0.001; r = -0.686). The spectrum of the latter has changed also very markedly. The prostacyclin PGI2-to-thromboxane TxA2 ratio increased significantly (p < 0.001). Beneficial effects of n-3 fatty acids have prevailed and this kind of treatment seems very encouraging also in NIDDM patients. The results are logically compatible with other authors' results pattern formed in 1990s. A slight rise in serum LDL needs a more detailed discussion since only its phenotype B ("small dense LDL particles") has been recently found to be atherogenic. (Tab. 2, Fig. 5, Ref. 15.) SN - 0006-9248 UR - https://www.unboundmedicine.com/medline/citation/9588078/[The_effect_of_n_3_fatty_acid_administration_on_selected_indicators_of_cardiovascular_disease_risk_in_patients_with_type_2_diabetes_mellitus]_ L2 - http://www.diseaseinfosearch.org/result/8215 DB - PRIME DP - Unbound Medicine ER -